Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, Tsavaris N, Pectasides D, Dimitriadis G, Kaltsas G. Koumarianou A, et al. Endocr Relat Cancer. 2012 Jan 9;19(1):L1-4. doi: 10.1530/ERC-11-0287. Print 2012 Feb. Endocr Relat Cancer. 2012. PMID: 22232542 Free PMC article. Clinical Trial. No abstract available.
Chemotherapy in NETs: When and how.
Angelousi A, Kaltsas G, Koumarianou A, Weickert MO, Grossman A. Angelousi A, et al. Among authors: koumarianou a. Rev Endocr Metab Disord. 2017 Dec;18(4):485-497. doi: 10.1007/s11154-017-9432-1. Rev Endocr Metab Disord. 2017. PMID: 28890993 Review.
Current best practice in the management of neuroendocrine tumors.
Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Tsoli M, et al. Among authors: koumarianou a. Ther Adv Endocrinol Metab. 2018 Oct 31;10:2042018818804698. doi: 10.1177/2042018818804698. eCollection 2019. Ther Adv Endocrinol Metab. 2018. PMID: 30800264 Free PMC article. Review.
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Chatzellis E, Angelousi A, Daskalakis K, Tsoli M, Alexandraki KI, Wachuła E, Meirovitz A, Maimon O, Grozinsky-Glasberg S, Gross D, Kos-Kudła B, Koumarianou A, Kaltsas G. Chatzellis E, et al. Among authors: koumarianou a. Neuroendocrinology. 2019;109(4):333-345. doi: 10.1159/000500135. Epub 2019 Jun 3. Neuroendocrinology. 2019. PMID: 31167197
Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms".
Chatzellis E, Daskalakis K, Angelousi A, Tsoli M, Alexandraki KI, Wachula E, Meirovitz A, Maimon O, Grozinsky-Glasberg S, Gross D, Kos-Kudła B, Koumarianou A, Kaltsas G. Chatzellis E, et al. Among authors: koumarianou a. Neuroendocrinology. 2020;110(1-2):158-160. doi: 10.1159/000503999. Epub 2019 Oct 10. Neuroendocrinology. 2020. PMID: 31597137 No abstract available.
Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study.
Koumarianou A, Pectasides D, Koliou GA, Dionysopoulos D, Kolomodi D, Poulios C, Skondra M, Sgouros J, Pentheroudakis G, Kaltsas G, Fountzilas G. Koumarianou A, et al. Biology (Basel). 2020 Mar 9;9(3):51. doi: 10.3390/biology9030051. Biology (Basel). 2020. PMID: 32182791 Free PMC article.
141 results